Rigel Pharmaceuticals RIGL ocadusertib — Deferred Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
Under the Lilly Agreement, we were responsible for 20% of the development costs for ocadusertib in the US, Europe, and Japan, up to a specified cap, and Lilly was responsible for funding the remainder of all development activities for ocadusertib and other non-CNS disease development candidates. In September 2023, we exercised our first opt-out right, and concurrently, our cost share obligation for ocadusertib development ended on April 1, 2024. Although we retained a right to opt back into co-funding to receive increased royalties, we notified Lilly in April 2025 that we would not exercise this option. As a result, we have no further development cost-sharing obligations. In connection with this decision, we released the $40.0 million remaining cost share liability and recognized the amount as contract revenues from collaboration in the second quarter of 2025. As of March 31, 2026 and December 31, 2025, there was no deferred revenue related to the Lilly Agreement.
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's ocadusertib — deferred revenue?
- Rigel Pharmaceuticals (RIGL) reported ocadusertib — deferred revenue of $0 in Q1 2026.
- What does ocadusertib — deferred revenue mean?
- Represents payments received from collaboration partners for a specific drug program that have not yet been recognized as revenue because performance obligations remain unfulfilled. This liability reflects future services or milestones that the company must deliver to earn the revenue. It provides insight into the timing of future revenue recognition and the status of ongoing contractual obligations.
Ask your AI about Rigel Pharmaceuticals's ocadusertib — deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
